Ocular Melanoma clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors
open to eligible people ages 18-70
A multicenter trial to investigate TBio-4101, an autologous, neoantigen-selected, tumor-reactive TIL product, in patients with advanced solid malignancies.
Irvine, California and other locations
Our lead scientists for Ocular Melanoma research studies include Ritesh Parajuli.
Last updated: